Brief Communication abstract


Nature Genetics 39, 157 - 158 (2006)
Published online: 31 December 2006 | doi:10.1038/ng1941

Epigenetic stem cell signature in cancer

Martin Widschwendter1, Heidi Fiegl1,2, Daniel Egle2, Elisabeth Mueller-Holzner2, Gilbert Spizzo3, Christian Marth2, Daniel J Weisenberger4, Mihaela Campan4, Joanne Young5, Ian Jacobs1 & Peter W Laird4

Top

Embryonic stem cells rely on Polycomb group proteins to reversibly repress genes required for differentiation. We report that stem cell Polycomb group targets are up to 12-fold more likely to have cancer-specific promoter DNA hypermethylation than non-targets, supporting a stem cell origin of cancer in which reversible gene repression is replaced by permanent silencing, locking the cell into a perpetual state of self-renewal and thereby predisposing to subsequent malignant transformation.

Top
  1. Department of Gynecological Oncology, Institute for Women's Health, University College London, London WC1E 6DH, UK.
  2. Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria.
  3. Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria.
  4. Departments of Surgery and of Biochemistry and Molecular Biology, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, USA.
  5. Molecular Cancer Epidemiology Laboratory, Queensland Institute for Medical Research, Herston 4006, Australia.

Correspondence to: Peter W Laird4 e-mail: plaird@usc.edu

Correspondence to: Martin Widschwendter1Daniel J Weisenberger4 e-mail: M.Widschwendter@ucl.ac.uk

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.


Extra navigation

Subscribe to Nature Genetics

Subscribe

Open Innovation Challenges

naturejobs

ADVERTISEMENT